



**Biocon Limited**  
20th KM, Hosur Road  
Electronic City  
Bangalore 560 100, India  
T 91 80 2808 2808  
F 91 80 2852 3423

CIN : L24234KA1978PLC003417

[www.biocon.com](http://www.biocon.com)

BIO/SECL/SG/2024-25/148

January 02, 2025

To The Manager, <b>BSE Limited</b> Department of Corporate Services Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001	To The Manager, <b>National Stock Exchange of India Limited</b> Corporate Communication Department Exchange Plaza, Bandra Kurla Complex Mumbai – 400 050
<b>Scrip Code - 532523</b>	<b>Scrip Symbol - Biocon</b>

Dear Sir/Madam,

**Subject: Notification to Stock Exchanges**

This is to inform you that Biocon Pharma Limited, a wholly owned subsidiary of the Company, has received approval for Tacrolimus capsule in 0.5mg, 1mg and 5mg strengths, from the National Medical Products Administration (NMPA), China. Tacrolimus is an immunosuppressant used in the treatment of organ transplant patients, which reduces the body's ability to reject a transplanted organ.

The approval further adds to Biocon's portfolio of complex drug products and will be commercialised in the region expeditiously.

The above information will also be available on the website of the Company at [www.biocon.com](http://www.biocon.com).

Kindly take the same on record and acknowledge.

Thanking You,

Yours faithfully,

For **Biocon Limited**

---

**Mayank Verma**  
**Company Secretary and Compliance Officer**  
**Membership No. A18776**